Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,159 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,025 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (560)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06041477 | Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC(HAIC) | recruiting | Phase 3 | 540 | Sun Yat-sen UniversityOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT02112656 | Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)(OPTIMA) | completed | Phase 3 | 554 | ImunonINDUSTRY | 14 | Aug 20, 2024 |
| clinicaltrials |
| NCT02989857 | Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)(ClarIDHy) | completed | Phase 3 | 187 | Institut de Recherches Internationales ServierOTHER | 6 | Aug 20, 2024 | clinicaltrials |
| NCT05833815 | Addition of Everolimus to Standard of Care in Carcinoma Gallbladder | unknown | Phase 2 / Phase 3 | 56 | Banaras Hindu UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05594927 | Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)(BESTPOP) | unknown | Phase 3 | 261 | Beijing Shenogen Biomedical Co., LtdINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT02856126 | HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC | completed | Phase 3 | 214 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06478108 | Interventional Software for Multi-immunotherapy of Solid Tumors | recruiting | Phase 2 / Phase 3 | 60 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03949231 | Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma | recruiting | Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT04047173 | RFA Versus SBRT for Recurrent Small HCC | completed | Phase 3 | 166 | Sun Yat-sen UniversityOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06434753 | Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease. | unknown | Phase 3 | 300 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT02109146 | Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma | completed | Phase 3 | 332 | Zhejiang UniversityOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT03773302 | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations | terminated | Phase 3 | 48 | QED Therapeutics, a BridgeBio companyINDUSTRY | 15 | May 8, 2024 | clinicaltrials |
| NCT00617981 | Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC) | completed | Phase 3 | 701 | ImunonINDUSTRY | 11 | May 3, 2024 | clinicaltrials |
| NCT06089369 | Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion | not yet recruiting | Phase 3 | 360 | Tongji HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT05738616 | Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study) | recruiting | Phase 3 | 196 | Wen TianfuOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT04103398 | TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma(TREAT) | completed | Phase 3 | 162 | Sun Yat-sen UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04560894 | SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 405 | Sinocelltech Ltd.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT02649153 | Effect of Smoked Plum and Chewing Gum on Postoperative Bowel Function Following Hepatic Resection(SP/GC-HCC) | completed | Phase 3 | 240 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02650271 | Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC | completed | Phase 3 | 240 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05062837 | Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | unknown | Phase 2 / Phase 3 | 62 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05711823 | Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC | unknown | Phase 3 | 300 | Guangxi Medical UniversityOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05910970 | Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation(PREVENT-2) | unknown | Phase 3 | 200 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02329860 | Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) | completed | Phase 3 | 400 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2024 | clinicaltrials |
| NCT06201065 | FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial | recruiting | Phase 3 | 200 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT01004978 | Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | Phase 3 | 235 | National Cancer Institute (NCI)NIH | 1 | Jan 3, 2024 | clinicaltrials |
| NCT04066491 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC | terminated | Phase 2 / Phase 3 | 309 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 15 | Nov 14, 2023 | clinicaltrials |
| NCT00716976 | Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy | completed | Phase 3 | 131 | Children's Oncology GroupNETWORK | 3 | Nov 9, 2023 | clinicaltrials |
| NCT03434379 | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma(IMbrave150) | completed | Phase 3 | 558 | Hoffmann-La RocheINDUSTRY | 17 | Oct 23, 2023 | clinicaltrials |
| NCT06089382 | A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection | not yet recruiting | Phase 3 | 104 | Tongji HospitalOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05250843 | TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC | unknown | Phase 2 / Phase 3 | 90 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT00658593 | Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer | terminated | Phase 3 | 19 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05976568 | A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 / Phase 3 | 668 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00699816 | Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients | completed | Phase 3 | 230 | GC Cell CorporationINDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT04797884 | Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma(ARTEMIS) | unknown | Phase 2 / Phase 3 | 166 | THERABIONIC INC.OTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05263219 | DEB-TACE+HAIC vs. HAIC for Large HCC | unknown | Phase 3 | 230 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02973685 | HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B. | completed | Phase 3 | 315 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT05608200 | Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC | recruiting | Phase 3 | 427 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT04163900 | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer | terminated | Phase 3 | 773 | NuCana plcOTHER | 15 | May 24, 2023 | clinicaltrials |
| NCT05866172 | HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC | unknown | Phase 3 | 264 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05862337 | Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. | recruiting | Phase 3 | 480 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 17, 2023 | clinicaltrials |
| NCT02853474 | Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy(EPIC-1511) | completed | Phase 3 | 480 | Centre Oscar LambretOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT05408221 | the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 576 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Mar 10, 2023 | clinicaltrials |
| NCT04387695 | SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT | unknown | Phase 3 | 54 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03236649 | The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects | terminated | Phase 3 | 89 | Beijing Shenogen Biomedical Co., LtdINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05718232 | SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)(SEARCH) | not yet recruiting | Phase 3 | 136 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT02438436 | Simo Decoction and Gum Chewing for Bowel Activity(SD/GC-HCC) | completed | Phase 3 | 180 | Guangxi Medical UniversityOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT02125396 | Adjuvant Radiotherapy Comparing TACE for Curative HCC(ARTC-HCC) | unknown | Phase 3 | 150 | Guangxi Medical UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein(REACH-2) | completed | Phase 3 | 399 | Eli Lilly and CompanyINDUSTRY | 20 | Jan 20, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Aug 27, 2024source: clinicaltrials